TY - JOUR
T1 - Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma
AU - Alama, Angela
AU - Merlo, Franco
AU - Chiara, Silvana
AU - Muttini, Maria Pia
AU - Guido, Tiziana
AU - Nicolò, Guido
AU - Conte, Pier Franco
AU - Ragni, Nicola
PY - 1992
Y1 - 1992
N2 - The relationship between tumour proliferative activity, evaluated by thymidine labelling index (TLI), clinicopathological variables and clinical outcome, was analysed in a series of 64 chemotherapy-resistant, ovarian cancer patients. The median TLI of 4.6% (range 0.01-45.7) was used as the cut-off to discriminate rapidly from slowly proliferating tumours. Univariate analyses showed a significant advantage in survival for patients with TLI ≤ 4.6 (P = 0.0004), ECOG performance status ≤ 1 (P = 0.0001) and residual disease after primary surgery ≤ 2 cm (P = 0.019). Multivariate analysis demonstrated that performance status was the only independent prognostic variable, although TLI was the last covariate removed from the Cox's regression model.
AB - The relationship between tumour proliferative activity, evaluated by thymidine labelling index (TLI), clinicopathological variables and clinical outcome, was analysed in a series of 64 chemotherapy-resistant, ovarian cancer patients. The median TLI of 4.6% (range 0.01-45.7) was used as the cut-off to discriminate rapidly from slowly proliferating tumours. Univariate analyses showed a significant advantage in survival for patients with TLI ≤ 4.6 (P = 0.0004), ECOG performance status ≤ 1 (P = 0.0001) and residual disease after primary surgery ≤ 2 cm (P = 0.019). Multivariate analysis demonstrated that performance status was the only independent prognostic variable, although TLI was the last covariate removed from the Cox's regression model.
UR - http://www.scopus.com/inward/record.url?scp=0026749258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026749258&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(92)90461-A
DO - 10.1016/0959-8049(92)90461-A
M3 - Article
C2 - 1627379
AN - SCOPUS:0026749258
VL - 28
SP - 1079
EP - 1080
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 6-7
ER -